Skip to content

MDMA: all studies

Page 74 of 352: studies 731 to 740 of 3,516, newest first. Back to the MDMA overview

Research

A comparison of self-reported sexual effects of alcohol, marijuana, and ecstasy in a sample of young adult nightlife attendees.

Psychology and sexuality 2018 Joseph J Palamar, Marybec Griffin-Tomas, Patricia Acosta et al.

Alcohol, marijuana, and ecstasy (3,4-methylenedioxymethamphetamine [MDMA], 'Molly') are among the most prevalent substances used by young adults; however, few studies have focused on the specific sexual effects associated with use. Examining subjective sexual effects (e.g. increased libido) associated with use can inform prevention efforts. Data were analysed from 679 nightclub and dance...

Reduced Efficacy of d-Amphetamine and 3,4-Methylenedioxymethamphetamine in Inducing Hyperactivity in Mice Lacking the Postsynaptic Scaffolding Protein SHANK1.

Frontiers in Molecular Neuroscience 2018 A Özge Sungur, Tobias M Redecker, Elena Andres et al.

Genetic defects in the three SH3 and multiple ankyrin repeat domains (SHANK) genes (SHANK1, SHANK2, and SHANK3) are associated with multiple major neuropsychiatric disorders, including autism spectrum disorder (ASD), schizophrenia (SCZ), and bipolar disorder (BPD). Psychostimulant-induced hyperactivity is a commonly applied paradigm to assess behavioral phenotypes related to BPD and considered...

Downregulation of the Vitamin D Receptor Regulated Gene Set in the Hippocampus After MDMA Treatment.

Frontiers in Pharmacology 2018 Peter Petschner, Noemi Balogh, Csaba Ádori et al.

The active ingredient of ecstasy, ±3,4-methylenedioxymethamphetamine (MDMA), in addition to its initial reinforcing effects, induces selective and non-selective brain damage. Evidences suggest that the hippocampus (HC), a central region for cognition, may be especially vulnerable to impairments on the long-run, nevertheless, transcription factors that may precede and regulate such chronic...

DOI: 10.3389/fphar.2018.01373 (opens in new tab) Full text (opens in new tab) Ecstasy Gene expression Hippocampus Long-term potentiation +2

Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances.

Handbook of experimental pharmacology 2018 Linda D. Simmler, Matthias E. Liechti

New psychoactive substances (NPS) with amphetamine-, aminoindan-, and benzofuran basic chemical structures have recently emerged for recreational drug use. Detailed information about their psychotropic effects and health risks is often limited. At the same time, it emerged that the pharmacological profiles of these NPS resemble those of amphetamine or 3,4-methylenedioxymethamphetamine (MDMA)....

The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985)

Drug Science, Policy and Law 2018 Torsten Passie 115 citations

3,4-Methylenedioxymethamphetamine (MDMA), also known as ecstasy, was first synthesized in 1912 but first reached widespread popularity as a legal alternative after the much sought-after recreational drug 3,4-methylenedioxy-amphetamine (MDA) was made illegal in 1970. Because of its benign, feeling-enhancing, and nonhallucinatory properties, MDMA was used by a few dozen psychotherapists in the...

Ecstasy-Belonging in Madagascar and Brazil

Oxford Scholarship Online December 21, 2017 Kélina Gotman

Choreomania became distinctly political. Missionary physicians and neuroscientists stationed in Madagascar and Brazil compared trance-like revolutionary uprisings to the literature on choreomania. Unlike earlier cases, however, these ‘movement disorders’, large-scale anti-colonial demonstrations characterized by shaking, frothing, falling, and visions—as well as, in Madagascar, ancestor...

Methylenedioxymethamphetamine (MDMA)-induced toxic leukoencephalopathy: a case report

December 5, 2017 H. Salem, T. Barton, Taha Ali et al.

ABSTRACT In recent years, ecstasy has become a very popular recreational drug. To date, very little data is available regarding its toxic side effects. Specifically, reports relating ecstasy use to the clinical diagnosis of leukoencephalopathy are quite rare. In this report, we present an interesting case of a 33-year-old female with a recent history of ecstasy abuse who presented with delirium...

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA

European Journal of Clinical Pharmacology December 2, 2017 Patrick Vizeli, Henriette E. Meyer zu Schwabedissen, Matthias E. Liechti 15 citations

Methylenedioxymethamphetamine (MDMA, ecstasy) is used recreationally and frequently leads to sympathomimetic toxicity. MDMA produces cardiovascular and subjective stimulant effects that were shown to partially depend on the norepinephrine transporter (NET)-mediated release of norepinephrine and stimulation of α 1 -adrenergic receptors. Genetic variants, such as single-nucleotide polymorphisms...

Differential effects of MDMA and cocaine on inhibitory avoidance and object recognition tests in rodents.

Neurobiology of Learning and Memory December 2017 María Pilar García-pardo, Jose Enrique De la Rubia Ortí, Maria Asunción Aguilar Calpe

Drug addiction continues being a major public problem faced by modern societies with different social, health and legal consequences for the consumers. Consumption of psychostimulants, like cocaine or MDMA (known as ecstasy) are highly prevalent and cognitive and memory impairments have been related with the abuse of these drugs. The aim of this work was to review the most important data of the...